Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
Completed · Phase 3 · NCT03633617
Conditions: Eosinophilic Esophagitis
At a glance
- Research payments reported, 2025
- $62,414
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 321
About the trial
- Sponsor
- Regeneron Pharmaceuticals (with Sanofi)
- Tested
- Dupilumab (drug), Placebo (drug)
- Dates
- Started 2018-09-24; completion 2022-06-07
- Results posted
- Yes
The primary objectives of the study by study part are: Part A: To determine the treatment effect of dupilumab compared with placebo in adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological and clinical measures and to inform/confirm the final sample size determination for Part B. Part B: To demonstrate the efficacy of dupilumab treatment compared with placebo in adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological and clinical measures. Part C: To assess the safety and efficacy of dupilumab treatment in adult and adolescent patients with EoE after up to 52 weeks of treatment as assessed by histological and …
From ClinicalTrials.gov, last updated 2023-06-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $62,414 in research payments for this study in 2025 (50 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $62,414
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.